USE OF t-ALP IN DIAGNOSIS OF MINERAL BONE DISEASE IN CKD PATIENTS ON DIALYSIS

Dr. Babita Bansal, Dr. Anupinder Thind, Dr. Deepak Kumar Agrawal, Dr. Jaspreet Takkar

Abstract


In patients of Chronic Kidney Disease (CKD), bone histology is routinely employed for the precise assessment of Mineral Bone Disease (MBD).  The search for reliable biochemical bone parameters has been ongoing. Estimation of t-ALP has been used as main biochemical indicator in this cross-sectional observational study on dialysis patients. Biochemical analysis of total alkaline phosphatase & intact parathormone of all cases were done using fully automated equipments. To see the association among different patterns of MBD, statistical tests like Chi-square and ANOVA were used. The statistical analysis with χ2 testing of the results revealed that MBD is significantly associated with t-ALP level.The present study does not accept the null hypothesis and suggests that there is a statistically significant association of t-ALP levels with bone mineral disease (altered parathormone levels) for CKD patients on haemodialysis.

Keywords


Alkaline Phosphatase, Chronic Kidney Disease, Haemodialysis.

Full Text:

PDF

References


Acton A. Bone fracture: New insights for the Healthcare Professional. Scholarly Edition 2013, Atlanta, Georgia, viewed 5 October 2017, .

Kidney Disease Improving Global Outcomes (KDIGO). Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD). J International Society of Nephrology (Int Kidney) 2009;76(Suppl. 113): Sv–Svi.

KDIGO. Clinical practice guideline update on diagnosis, evaluation, prevention and treatment of CKD-MBD. Open public Review of the draft 2016: 01-45.

Valson AT, Sundaram M and Jacob CK. Profile of incident chronic kidney disease related-mineral bone disorders in chronic kidney disease Stage 4 and 5: A hospital based cross-sectional survey. Indian Journal of Nephrology 2014; 24(2):97-107.

Okoye JU, Arodiwe EB, Ulasi II, Ijoma CK, Onodugo OD. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu. South-East Nigeria. Afri Health Sci 2015;15(3): 941-8.

Vhora RS, Munde A, Bale C and Kakrani AL. Correlation of serum parathyroid hormone, with mineral bone disease in chronic kidney disease patients. Medical Journal of Dr. D.Y. Patil University 2015. Published by Wolters Kluwer.

Iwasaki Y, Kazama JJ & Fukagawa M. Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. Bio Medical Research International 2017; 2017:1-11.

Heinrich D, Bruland O, Guise TA, Suzuki H and Sartor O. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Future Oncol 2018;14(24):2543-2556.

Gooz, M. Chronic Kidney Disease. The New Kidney and Bone Disease: Chronic kidney disease –Mineral and Bone Disorder (CKD-MBD). NIH 2019: 30, viewed 07 Nov 2019,

Urena P, Ferreira A, Kung VT, Morieux C, Simon P, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res, 1995;10(6):932-39.

Sardiwal S, Gardham C, Coleman AE, Stevens PE, Delaney MP and Lamb EJ. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int, 2012;82:100–5.

Jabbar Z, Aggarwal PK, Chandel N, Khandewal N, Sakhuja V and Jha V. Noninvasive assessment of bone mineral status in Indian CKD population. Indian J Nephrol 2007; 17:93.

Budhathoki AS, Khatri D, Singh TA and Sapkota A. Study of Vitamin D, Parathormone, calcium and phosphorus levels in patients with End Stage Renal Disease undergoing haemodialysis and their interpretation. International Journal of Advanced Research 2015;3(11):1151 –54.


Refbacks

  • There are currently no refbacks.